Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4065967 in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.
Official title: A Phase 1, Randomized, Open-Label, Crossover Study to Investigate the Relative Bioavailability of LY4065967 Formulations in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-06
Completion Date
2026-07
Last Updated
2026-05-26
Healthy Volunteers
Yes
Conditions
Interventions
LY4065967 Tablet
Administered orally
LY4065967 Formulated Capsule
Administered orally
LY4065967 Capsule
Administered orally
Locations (2)
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States